Norway's pharmaceutical revolution
Knut Sogner
Bok · Engelsk · 2022
| Omfang | x, 253 sider
|
|---|---|
| Opplysninger | "The academic-business effort of a handful of primarily large nations - USA, Germany, Great Britain, Switzerland and France - culminated in the 1930s and 1940s in a number of potent new therapeutics that with subsequent new products over the next decades created what is known as "The pharmaceutical revolution." This was to a great degree based on academic-business collaboration and proved difficult to accomplish for other large nations like Japan, China, India, Italy, Spain and Russia, to mention some, not to speak of smaller nations. Companies in the smaller Scandinavian countries were, however, able in a narrow band of products to join the group of pioneering nations and become original contributors to the pharmaceutical revolution. This book highlights the particular difficult Norwegian experience that counted one major breakthrough, and which shows just how challenging it was to join the elite countries in pharmaceuticals. The small and traditional generics company Nyegaard & Co. succeeded only in 1969 with the breakthrough of a new principle for X-ray contrast media. Until the 1960s, it had been distracted and hindered by the national drugs policy. The research success can largely be attributed to corporate competence and corporate initiatives to exploit the Scandinavian rather than the Norwegian medical ecosystem. And the subsequent innovations were made commercial successes through the building of international partnerships with larger corporations. Success came at a price, though, for at the very time the commercial success was at its greatest in the 1990s, the organization had lost its innovative claw"--
|
| ISBN | 9780192869005
|